• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伴有杂合性甲状腺素转运蛋白(TTR)突变的遗传性软脑膜转甲状腺素蛋白淀粉样变性:一例报告及文献综述

Hereditary leptomeningeal transthyretin amyloidosis with heterozygous TTR mutation: a case report and literature review.

作者信息

Chen Hong-Tao, Tian You-Jun, Zhang Jue, Xiao Bing-Rong, Yang Ke, Zhang Ya-Li

机构信息

Department of Diagnostic Imaging Center, First People's Hospital of Tianmen, Jingling people Avenue East No. 1, Tianmen City, 431701, Hubei Province, China.

出版信息

Orphanet J Rare Dis. 2025 May 5;20(1):213. doi: 10.1186/s13023-025-03736-x.

DOI:10.1186/s13023-025-03736-x
PMID:40325410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12051266/
Abstract

OBJECTIVE

This study aimed to characterize the clinical and neuroimaging features of hereditary leptomeningeal transthyretin amyloidosis (hATTR-LA), a dominant inheritance disorder caused by a heterozygous TTR gene mutation.

METHODS

A comprehensive retrospective evaluation was conducted, incorporating detailed clinical records, multimodal neuroimaging findings, and a systematic review of the literature to contextualize the observations.

RESULTS

The patient was a 55-year-old male who presented with chronic central nervous system symptoms, including sensory-motor peripheral neuropathy and progressive visual impairment. Cerebrospinal fluid analysis revealed elevated protein levels. Neuroimaging showed progressive leptomeningeal hyperdensity on CT and characteristic linear thickening with enhancement of the leptomeninges on MRI, involving both cerebral and spinal regions. Genetic testing confirmed the diagnosis by identifying a heterozygous c.265T > C (p.Y89H) pathogenic variant in exon 3 of the TTR gene, classified as pathogenic according to ACMG guidelines.

CONCLUSION

Multimodal imaging provides valuable, non-invasive insights for diagnosing hATTR-LA, enhancing diagnostic accuracy and informing clinical management of this rare condition.

摘要

目的

本研究旨在描述遗传性软脑膜转甲状腺素蛋白淀粉样变性(hATTR-LA)的临床和神经影像学特征,这是一种由杂合型TTR基因突变引起的显性遗传疾病。

方法

进行了全面的回顾性评估,纳入详细的临床记录、多模态神经影像学检查结果,并对文献进行系统回顾,以将观察结果置于背景中。

结果

患者为一名55岁男性,表现为慢性中枢神经系统症状,包括感觉运动性周围神经病和进行性视力损害。脑脊液分析显示蛋白水平升高。神经影像学检查显示,CT上软脑膜密度逐渐增高,MRI上软脑膜呈特征性线性增厚并强化,累及脑和脊髓区域。基因检测通过在TTR基因第3外显子中鉴定出一个杂合型c.265T>C(p.Y89H)致病变异确诊,根据美国医学遗传学与基因组学学会(ACMG)指南,该变异被分类为致病变异。

结论

多模态成像为hATTR-LA的诊断提供了有价值的非侵入性见解,提高了诊断准确性,并为这种罕见疾病的临床管理提供了信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c50/12051266/88f5b1cf6011/13023_2025_3736_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c50/12051266/1ab8ec386e39/13023_2025_3736_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c50/12051266/88f5b1cf6011/13023_2025_3736_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c50/12051266/1ab8ec386e39/13023_2025_3736_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c50/12051266/88f5b1cf6011/13023_2025_3736_Fig2_HTML.jpg

相似文献

1
Hereditary leptomeningeal transthyretin amyloidosis with heterozygous TTR mutation: a case report and literature review.伴有杂合性甲状腺素转运蛋白(TTR)突变的遗传性软脑膜转甲状腺素蛋白淀粉样变性:一例报告及文献综述
Orphanet J Rare Dis. 2025 May 5;20(1):213. doi: 10.1186/s13023-025-03736-x.
2
A mutation in transthyretin gene in a Mexican patient leading to hereditary amyloidosis: a case report.一名墨西哥患者甲状腺转运蛋白基因突变导致遗传性淀粉样变性:病例报告
J Med Case Rep. 2025 Aug 4;19(1):384. doi: 10.1186/s13256-025-05308-w.
3
Novel Pathogenic Variant c.258A>C, p.(Glu86Asp) in the Gene in a Bulgarian Patient with Hereditary Transthyretin Amyloidosis.保加利亚一名遗传性转甲状腺素蛋白淀粉样变性患者的基因中发现新型致病变异c.258A>C,p.(Glu86Asp) 。
Genes (Basel). 2025 Jun 22;16(7):726. doi: 10.3390/genes16070726.
4
Hereditary Transthyretin Amyloidosis: Genetic Characterization of the P.Val142Ile Variant in a Calabrian Kindred.遗传性转甲状腺素蛋白淀粉样变性:卡拉布里亚家族中P.Val142Ile变异体的遗传学特征
Genes (Basel). 2025 Aug 14;16(8):960. doi: 10.3390/genes16080960.
5
Effects of Tafamidis Meglumine on Transient Focal Neurological Episodes and Meningeal Contrast Enhancement in Hereditary Transthyretin-Related Meningeal Amyloidosis: Report of Two Patients Carrying the c.265T>C (p.Y89H) Variant.葡甲胺氯苯吩嗪对遗传性转甲状腺素蛋白相关脑膜淀粉样变性中短暂性局灶性神经发作和脑膜对比增强的影响:两例携带c.265T>C(p.Y89H)变异患者的报告
Brain Behav. 2025 Sep;15(9):e70856. doi: 10.1002/brb3.70856.
6
Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center.遗传性转甲状腺素蛋白淀粉样变性的遗传和临床特征:日本一家转诊中心的十年经验
Orphanet J Rare Dis. 2025 Sep 2;20(1):474. doi: 10.1186/s13023-025-04006-6.
7
Etiologic Diagnosis of Neuropathies Based on First-Line Screening of TTR Gene Mutations.基于转甲状腺素蛋白(TTR)基因突变一线筛查的神经病病因诊断
J Peripher Nerv Syst. 2025 Sep;30(3):e70043. doi: 10.1111/jns.70043.
8
Transthyretin variants impact blood-nerve barrier and neuroinflammation in amyloidotic neuropathy.转甲状腺素蛋白变体影响淀粉样变性神经病中的血神经屏障和神经炎症。
Brain. 2025 Jul 7;148(7):2537-2550. doi: 10.1093/brain/awaf028.
9
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.转甲状腺素蛋白淀粉样变性神经病的 inotersen 的长期疗效和安全性:NEURO-TTR 开放标签扩展 3 年更新。
J Neurol. 2022 Dec;269(12):6416-6427. doi: 10.1007/s00415-022-11276-8. Epub 2022 Jul 31.
10
Intracutaneous Amyloid Deposition is Associated With Nerve Conduction Studies Deterioration in Presumed Asymptomatic Pathogenic Variant TTR Carriers.皮内淀粉样蛋白沉积与疑似无症状致病性变异型转甲状腺素蛋白(TTR)携带者的神经传导研究恶化有关。
Eur J Neurol. 2025 Jul;32(7):e70277. doi: 10.1111/ene.70277.

本文引用的文献

1
Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis.在遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病管理中使用帕替拉韦的实用指南。
Ther Clin Risk Manag. 2023 Nov 27;19:973-981. doi: 10.2147/TCRM.S361706. eCollection 2023.
2
[Case of hereditary Y69H (p.Y89H) transthyretin variant leptomeningeal amyloidosis presenting with drop attacks and recurrent transient language disorder].[遗传性Y69H(p.Y89H)转甲状腺素蛋白变异型软脑膜淀粉样变性伴猝倒发作和复发性短暂性语言障碍病例]
Rinsho Shinkeigaku. 2023 Oct 25;63(10):650-655. doi: 10.5692/clinicalneurol.cn-001852. Epub 2023 Sep 30.
3
Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China.
中国遗传性转甲状腺素蛋白淀粉样变性患者的临床表型和遗传特征。
Orphanet J Rare Dis. 2022 Sep 2;17(1):337. doi: 10.1186/s13023-022-02481-9.
4
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.遗传性转甲状腺素蛋白淀粉样变性病诊断与管理的新方法。
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668-678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7.
5
Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis.G47R遗传性转甲状腺素蛋白淀粉样变性的早发性软脑膜表现
Neurol Clin Pract. 2021 Oct;11(5):e757-e759. doi: 10.1212/CPJ.0000000000001054.
6
Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.转甲状腺素蛋白心脏淀粉样变的治疗进展:现有及新兴疗法。
Pharmacotherapy. 2021 Dec;41(12):1081-1091. doi: 10.1002/phar.2639. Epub 2021 Oct 30.
7
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.CRISPR-Cas9 体内基因编辑治疗转甲状腺素蛋白淀粉样变性。
N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.
8
Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management.加拿大遗传性转甲状腺素蛋白淀粉样变性多发性神经病管理指南。
Can J Neurol Sci. 2022 Jan;49(1):7-18. doi: 10.1017/cjn.2021.34. Epub 2021 Feb 26.
9
Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China.中国转甲状腺素蛋白相关家族性淀粉样多神经病的临床与遗传学特征
Chin Med J (Engl). 2020 Nov 5;133(21):2616-2618. doi: 10.1097/CM9.0000000000001094.
10
Oculoleptomeningeal Amyloidosis Due to Transthyretin p.Y89H (Y69H) Variant.由转甲状腺素蛋白p.Y89H(Y69H)变体引起的眼软脑膜淀粉样变性
J Neuropathol Exp Neurol. 2020 Oct 1;79(10):1134-1136. doi: 10.1093/jnen/nlaa075.